Dutch Regulators Investigate Biogen Over MS Drug Testing Practices
Dutch antitrust regulators are investigating allegations that Biogen may have abused its dominant position in the market for multiple sclerosis treatments and associated blood tests. The Netherlands Authority for Consumers and Markets (ACM) is probing whether Biogen reserved a test for patients treated with Tysabri, its MS drug, while refusing to make the test available…









